Clinical trials: Histological Response
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Myeloid Leukemia
Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.
The main purpose of this study was to evaluate the rate of deep molecular response (MR4.5) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase chronic myeloid leukemia (CML) using EUTOS…
- Trial name
- NILOdeepR (NCT02546674)
- Testing
- Nilotinib
- Where
- 70 sites in Germany
- Volunteers
- 171 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00002623
- Testing
- carboplatin, cisplatin, conventional surgery
- Where
- 30 sites in Belgium, France and 3 more
- Volunteers
- 640 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Myeloid Leukemia, Acute
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
This study aims to analyze patients with mutated FLT3 AML treated with specific therapy by means of molecular characterization methods, to identify the presence of clones and subclones at onset and to be able to follow their…
- Trial name
- CLEV-LAM-2022 (NCT06764459)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Esophageal Squamous Cell Carcinoma (ESCC)
Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal squamous cell carcinoma (ESCC) is a common and aggressive malignancy with poor prognosis, particularly in patients with locally advanced disease.
- Trial name
- Keystone006 (NCT07721103)
- Testing
- Neoadjuvant Chemoimmunotherapy (Tislelizumab Plus Paclitaxel and Cisplatin), Sequential Chemoradiotherapy
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma, Pathological Complete Response
Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features
This multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy before surgery at three…
- Trial name
- pCR-ESCC (NCT07181850)
- Testing
- Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Nanjing Medical University
Squamous Cell Carcinoma
Study of the Association Between Tumor Microenvironment Macrophages and Treatment Response in Squamous Cell Carcinoma of the Anal Canal
Squamous cell carcinoma of the anal canal is a relatively rare cancer (less than 3% of digestive cancers) but its incidence has been increasing in recent decades, probably because of its association with HPV (human…
- Trial name
- MACARAN (NCT05019235)
- Where
- France
- Volunteers
- 154 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Cholangiocarcinoma
Liquid Biopsy MonitORing Of CholangioCarcinOma for Treatment Response and Prognostic Outcomes (MOROCCO)
This study explores the potential value of a new blood test approach to detect measurable residual disease or early recurrence/progression in patients with cholangiocarcinoma.
- Trial name
- NCT06474091
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Hodgkin's Lymphoma
A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)
The primary objective was to provide drug to ongoing patients who were receiving panobinostat and to characterize the safety and tolerability of panobinostat in patients with HL after achieving a complete response following…
- Trial name
- PATH (NCT01034163)
- Testing
- Panobinostat
- Where
- 35 sites in United States, Australia and 12 more
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma
This early phase I pilot trial studies how well patient-derived xenografts work in personalizing treatment for patients with mantle cell lymphoma that has come back (relapsed) or that isn't responding to treatment (refractory).
- Trial name
- NCT03219047
- Testing
- Best Practice, Ibrutinib, Patient Derived Xenograft
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma
Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
The primary objective of this study is to document efficacy and safety data in a real-world setting of Chinese multiple myeloma patients who have received at least one prior therapy treated with REVLIMID (lenalidomide).
- Trial name
- NCT01947309
- Testing
- Revlimid (lenalidomide)
- Where
- 17 sites in China
- Volunteers
- 176 people
- Sponsor
- Celgene
Glioblastoma Multiforme, Glioblastoma
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
Subjects will receive standard chemotherapy and Tumor Treated Fields (TTFields) and will also receive Carvedilol for 4 cycles of treatment.
- Trial name
- NCT03861598
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- West Virginia University
Melanoma
Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker
Explore the association between intensity of 11C-methyl-L-tryptophan (C11-AMT) positron emission tomography (PET) at baseline, as measured by mean standardized uptake value (SUVmax) at each lesion, total tumor metabolic volume…
- Trial name
- NCT03089606
- Testing
- FDG PET/CT scan, C11-AMT PET scan, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ovarian Cancer
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00002819
- Testing
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride
- Where
- 64 sites in United States
- Sponsor
- Gynecologic Oncology Group
Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase
Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal…
- Trial name
- MACS0911 (NCT01043874)
- Testing
- Nilotinib
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Follicular Lymphoma
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
- Conditions
- Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
- Trial name
- NCT06510361
- Testing
- Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer, Genitourinary Cancer
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
The goal of this clinical research study is to measure the amount of inflammatory proteins inside the body before and after lymphatico-venular bypass surgery.
- Conditions
- Breast Cancer, Genitourinary Cancer, Malignant Female Reproductive System Neoplasm, Melanoma
- Trial name
- NCT01433302
- Testing
- Punch Biopsy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Prostate cancer (PCa) is the most frequently diagnosed cancer in men and second leading cause of cancer-related death. Men with PCa have a wide range of possible outcomes if the cancer has not spread and is classified as…
- Trial name
- SChLAP/IDC (NCT04176081)
- Testing
- Darolutamide, Degarelix, Radiation Therapy
- Where
- Canada
- Volunteers
- 208 people
- Sponsor
- University Health Network, Toronto
ASTHMA
Risk Factors Associated to Difficult-to-control Asthma
Several studies have demonstrated the efficacy of asthma treatment but despite being correctly diagnosed, conveniently prescribed and adherent to the therapeutics, 5% to 10% of asthmatics do not reach disease control.
- Trial name
- NCT01089322
- Testing
- inhaled corticosteroid plus LABA plus oral corticosteroid
- Where
- Brazil
- Volunteers
- 74 people
- Sponsor
- Rafael Stelmach
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.